Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma

Fujiwara, Naoto; Singal, Amit G.; Hoshida, Yujin

doi:10.1002/hep.30813

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COX-2 inhibition increases with higher doses of ASA, which may explain ASA's dose and duration dependent reduction in the development of HCC. 6,12,13 Increased COX-2 expression is associated with activation of nuclear factor κ B and mammalian target of rapamycin proliferative pathways as well as silencing of many tumor suppressor genes. 14 By inhibiting COX-2, ASA may inhibit these downstream oncogenic pathways.…”

Section: Discussionmentioning

confidence: 99%

Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma

Singh

Wozniak

Cotler

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer and cancer-related mortality worldwide. Studies have suggested that aspirin (ASA) and statins may be associated with a decrease in incident HCC. Goals: We aimed to evaluate the effect of ASA and statin use on the incidence of HCC in a prospective cohort of patients with liver cirrhosis and to identify if there was an increased risk of esophageal variceal hemorrhage (VH) in patients with ASA use. Study: We conducted a retrospective study of 521 patients with data collected from July 1, 2012 to December 31, 2017. We used competing risk analysis to assess the association between risk factors and HCC; and the association between ASA and VH. Results: ASA use alone was associated with a decreased incidence of HCC in the univariate and multivariate models; [hazard ratio (HR) confidence interval (CI): 0.348 (0.124-0.976); P=0.0448] and [HR (CI): 0.266 (0.094-0.755); P=0.0129, respectively]. The combination of ASA and statin use was associated with a decreased hazard of HCC [HR (CI): 0.15 (0.036-0.624); P=0.0090] and this remained statistically significant in the multivariable model [HR (CI): 0.113 (0.026-0.483); P=0.0033]. Among daily ASA users compared with non-users, there was not a significant increase in risk of VH. Conclusions: Daily ASA use was associated with a decrease risk of incident HCC. The combination of daily ASA use and statin use decreased the risk of incident HCC suggesting there is beneficial interaction. Finally, no excess VH was observed in daily ASA users compared with non-users.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma

Singh

Wozniak

Cotler

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…However, we think that the effects of minimum duration of aspirin therapy on HCC incidence can be negligible because previous studies indicated that a long-term period of aspirin exposure was needed to observe significant decrease of HCC incidence. [ 8 , 27 ]…”

Section: Discussionmentioning

confidence: 99%

Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis

Shin

Lee

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…Consistent aspirin use over 6 years reduced colorectal cancer risk among men ( Chan et al, 2008 ). Aspirin use over 10 years significantly reduced HCC incidence while the use for 5–10 years only achieved marginal reduction ( Fujiwara et al, 2019 ). Pharmacokinetic interaction with other anti-cancer drugs also affected the effectiveness of NSAIDs.…”

Section: Discussionmentioning

confidence: 99%

Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

Lai

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Inflammatory processes are essential for innate immunity and contribute to carcinogenesis in various malignancies, such as colorectal cancer, esophageal cancer and lung cancer. Pharmacotherapies targeting inflammation have the potential to reduce the risk of carcinogenesis and improve therapeutic efficacy of existing anti-cancer treatment. Non-steroidal anti-inflammatory drugs (NSAIDs), comprising a variety of structurally different chemicals that can inhibit cyclooxygenase (COX) enzymes and other COX-independent pathways, are originally used to treat inflammatory diseases, but their preventive and therapeutic potential for cancers have also attracted researchers’ attention. Pharmacogenomic variability, including distinct genetic characteristics among different patients, can significantly affect pharmacokinetics and effectiveness of NSAIDs, which might determine the preventive or therapeutic success for cancer patients. Hence, a more comprehensive understanding in pharmacogenomic characteristics of NSAIDs and cancer-related inflammation would provide new insights into this appealing strategy. In this review, the up-to-date advances in clinical and experimental researches targeting cancer-related inflammation with NSAIDs are presented, and the potential of pharmacogenomics are discussed as well.

show abstract

Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma

Cited by 6 publications

References 9 publications

Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma

Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma

Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis

Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

Contact Info

Product

Resources

About